208 related articles for article (PubMed ID: 10568822)
21. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.
Nicoletti MI; Lucchini V; Massazza G; Abbott BJ; D'Incalci M; Giavazzi R
Ann Oncol; 1993 Feb; 4(2):151-5. PubMed ID: 8095399
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice.
Alagoz T; Buller RE; Anderson B; Terrell KL; Squatrito RC; Niemann TH; Tatman DJ; Jebson P
Cancer; 1995 May; 75(9):2313-22. PubMed ID: 7536123
[TBL] [Abstract][Full Text] [Related]
24. FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.
Naoe Y; Inami M; Matsumoto S; Takagaki S; Fujiwara T; Yamazaki S; Kawamura I; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
Jpn J Cancer Res; 1998 Dec; 89(12):1306-17. PubMed ID: 10081492
[TBL] [Abstract][Full Text] [Related]
25. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
26. Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response.
Klostergaard J; Auzenne E; Ghosh S; Farquhar D; Rivera B; Price RE
Int J Gynecol Cancer; 2006; 16 Suppl 1():111-7. PubMed ID: 16515577
[TBL] [Abstract][Full Text] [Related]
27. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy.
Massazza G; Tomasoni A; Lucchini V; Allavena P; Erba E; Colombo N; Mantovani A; D'Incalci M; Mangioni C; Giavazzi R
Int J Cancer; 1989 Sep; 44(3):494-500. PubMed ID: 2777413
[TBL] [Abstract][Full Text] [Related]
28. Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factor.
Malik ST; East N; Boraschi D; Balkwill FR
Br J Cancer; 1992 May; 65(5):661-6. PubMed ID: 1586593
[TBL] [Abstract][Full Text] [Related]
29. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
30. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
[TBL] [Abstract][Full Text] [Related]
31. Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer.
Friedlander ML; Russell P; Taylor IW; Tattersall MH
Br J Cancer; 1985 Mar; 51(3):319-33. PubMed ID: 3882111
[TBL] [Abstract][Full Text] [Related]
32. Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model.
Gomez-Roman N; McGregor F; Wheate NJ; Plumb JA
J Ovarian Res; 2015 Sep; 8():62. PubMed ID: 26384969
[TBL] [Abstract][Full Text] [Related]
33. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin.
Drees M; Dengler WM; Hendriks HR; Kelland LR; Fiebig HH
Eur J Cancer; 1995; 31A(3):356-61. PubMed ID: 7786602
[TBL] [Abstract][Full Text] [Related]
34. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
Rose WC; Basler GA
In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
[TBL] [Abstract][Full Text] [Related]
35. Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft.
Pratesi G; Manzotti C; Tortoreto M; Audisio RA; Zunino F
Br J Cancer; 1991 Jan; 63(1):71-4. PubMed ID: 1989668
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice.
Molpus KL; Koelliker D; Atkins L; Kato DT; Buczek-Thomas J; Fuller AF; Hasan T
Int J Cancer; 1996 Nov; 68(5):588-95. PubMed ID: 8938139
[TBL] [Abstract][Full Text] [Related]
37. Experimental antitumour activity of S 16020-2 in a panel of human tumours.
Kraus-Berthier L; Guilbaud N; Jan M; Saint-Dizier D; Rouillon MH; Burbridge MF; Pierré A; Atassi G
Eur J Cancer; 1997 Oct; 33(11):1881-7. PubMed ID: 9470851
[TBL] [Abstract][Full Text] [Related]
38. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
[TBL] [Abstract][Full Text] [Related]
39. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
40. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
Manenti L; Riccardi E; Marchini S; Naumova E; Floriani I; Garofalo A; Dossi R; Marrazzo E; Ribatti D; Scanziani E; Bani M; Belotti D; Broggini M; Giavazzi R
Mol Cancer Ther; 2005 May; 4(5):715-25. PubMed ID: 15897235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
